Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin as Treatment for Alcohol Use Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meets DSM-5 criteria for current alcohol use disorder~* Reports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days~* Between the ages of 18 and 65~* Able to provide informed consent and comply with study procedures~Exclusion Criteria:~* Subjects with any current psychiatric disorder as defined by DSM-5, other than AUD, that in the investigator's judgment might require intervention over the course of the study.~* Subjects receiving psychotropic medication treatment~* Evidence of moderate-to-severe alcohol withdrawal (CIWA-Ar \> 13)~* History of alcohol withdrawal seizures or alcohol withdrawal delirium~* History of allergic reaction to candidate medication (pregabalin)~* Pregnancy, lactation, or failure in females patients to use adequate contraceptive methods~* Unstable physical disorders which might make participation hazardous~* Subjects who have a current DSM-5 diagnosis of moderate or severe substance use disorder, with the exception of alcohol, nicotine and caffeine use disorders. A diagnosis of a mild substance use disorder will not be exclusionary, as long as the current primary substance use disorder is alcohol.~* Are legally mandated to participate in alcohol use disorder treatment program~* Cognitively impaired

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- pregabalin (Type: EXPERIMENTAL): pregabalin up to daily dose of 600 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).